{
    "organizations": [],
    "uuid": "270eb3f08c43185e9d82c312df7910ee60affb2f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/johnsonjohnson-fda/fda-approves-jj-prostate-cancer-treatment-idUSL4N1Q45QR",
    "ord_in_thread": 0,
    "title": "FDA approves J&J prostate cancer treatment",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 14 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnsonâ€™s Erleada treatment for use with prostate cancer patients whose cancer has not spread but continues to grow despite hormone therapy.\nThe drug is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer, the FDA said in a statement. (Reporting by Manas Mishra in Bengaluru; editing by Patrick Graham)\n ",
    "published": "2018-02-15T02:48:00.000+02:00",
    "crawled": "2018-02-15T20:23:59.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "food",
        "drug",
        "administration",
        "wednesday",
        "approved",
        "johnson",
        "johnson",
        "erleada",
        "treatment",
        "use",
        "prostate",
        "cancer",
        "patient",
        "whose",
        "cancer",
        "spread",
        "continues",
        "grow",
        "despite",
        "hormone",
        "therapy",
        "drug",
        "first",
        "treatment",
        "prostate",
        "cancer",
        "fda",
        "said",
        "statement",
        "reporting",
        "manas",
        "mishra",
        "bengaluru",
        "editing",
        "patrick",
        "graham"
    ]
}